FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971434622> ?p ?o ?g. }

• W2971434622 abstract "Testicular cancer is one of the few tumor types that have not yet benefited from targeted therapy. Still no new active agents for treating this cancer have been identified over the past 15 years. Once patients are refractory to cisplatin-based chemotherapy, they will be expected to die from testicular cancer. This report describes a 21-year-old man who was refractory to chemotherapy and immunotherapy. Whole exome sequencing and low-depth whole genome sequencing confirmed the KRAS gene amplification, which may lead to the tumor cells' progression and proliferation. After discussion at the molecular tumor board, the patient was offered paclitaxel, carboplatin, and sorafenib (CPS) based on a phase III clinical trial of melanoma with KRAS gene copy gains. After treatment with CPS, the patient achieved excellent curative effects. Because of a nearly 50% frequency of KRAS amplification in chemotherapy-refractory testicular germ cells, CPS regimen may provide a new therapy, but it still warrants further validation in clinical studies. KEY POINTS: Chemotherapy-refractory testicular cancer has a very poor prognosis resulting in a lack of effective targeted therapies. KRAS gene amplification occurs in nearly 20% of testicular cancer and 50% of chemotherapy-refractory testicular cancer. KRAS amplification may activate the MAPK signaling pathway, and inhibition of MAPK by sorafenib combined with paclitaxel and carboplatin could be a viable option based on a phase III clinical trial of melanoma.To the authors' knowledge, this is the first report of response to sorafenib-based combination targeted therapy in a patient with chemotherapy-refractory testicular cancer.Clinical genomic profiling can confirm copy number variation of testicular cancer and provide insights on therapeutic options." @default.
• W2971434622 created "2019-09-12" @default.
• W2971434622 creator A5002039083 @default.
• W2971434622 creator A5011378633 @default.
• W2971434622 creator A5023011217 @default.
• W2971434622 creator A5023214008 @default.
• W2971434622 creator A5023271869 @default.
• W2971434622 creator A5026197259 @default.
• W2971434622 creator A5046597133 @default.
• W2971434622 creator A5051238737 @default.
• W2971434622 creator A5055689235 @default.
• W2971434622 creator A5056204605 @default.
• W2971434622 creator A5065073273 @default.
• W2971434622 creator A5073216396 @default.
• W2971434622 creator A5074986594 @default.
• W2971434622 creator A5078632164 @default.
• W2971434622 creator A5088870232 @default.
• W2971434622 date "2019-09-06" @default.
• W2971434622 modified "2023-09-25" @default.
• W2971434622 title "Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy‐Refractory Testicular Tumors" @default.
• W2971434622 cites W1951627640 @default.
• W2971434622 cites W1984742410 @default.
• W2971434622 cites W1997533142 @default.
• W2971434622 cites W1999966467 @default.
• W2971434622 cites W2021986319 @default.
• W2971434622 cites W2039945054 @default.
• W2971434622 cites W2056790195 @default.
• W2971434622 cites W2068696123 @default.
• W2971434622 cites W2070396671 @default.
• W2971434622 cites W2070515723 @default.
• W2971434622 cites W2080719056 @default.
• W2971434622 cites W2136925048 @default.
• W2971434622 cites W2150840254 @default.
• W2971434622 cites W2168076926 @default.
• W2971434622 cites W2225530246 @default.
• W2971434622 cites W2284518822 @default.
• W2971434622 cites W2510820774 @default.
• W2971434622 cites W2522030015 @default.
• W2971434622 cites W2624983637 @default.
• W2971434622 cites W2781525129 @default.
• W2971434622 cites W2796153844 @default.
• W2971434622 cites W2804957989 @default.
• W2971434622 cites W2807733000 @default.
• W2971434622 cites W2883118933 @default.
• W2971434622 cites W4211258097 @default.
• W2971434622 doi "https://doi.org/10.1634/theoncologist.2019-0295" @default.
• W2971434622 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6975956" @default.
• W2971434622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31492770" @default.
• W2971434622 hasPublicationYear "2019" @default.
• W2971434622 type Work @default.
• W2971434622 sameAs 2971434622 @default.
• W2971434622 citedByCount "4" @default.
• W2971434622 countsByYear W29714346222021 @default.
• W2971434622 countsByYear W29714346222022 @default.
• W2971434622 countsByYear W29714346222023 @default.
• W2971434622 crossrefType "journal-article" @default.
• W2971434622 hasAuthorship W2971434622A5002039083 @default.
• W2971434622 hasAuthorship W2971434622A5011378633 @default.
• W2971434622 hasAuthorship W2971434622A5023011217 @default.
• W2971434622 hasAuthorship W2971434622A5023214008 @default.
• W2971434622 hasAuthorship W2971434622A5023271869 @default.
• W2971434622 hasAuthorship W2971434622A5026197259 @default.
• W2971434622 hasAuthorship W2971434622A5046597133 @default.
• W2971434622 hasAuthorship W2971434622A5051238737 @default.
• W2971434622 hasAuthorship W2971434622A5055689235 @default.
• W2971434622 hasAuthorship W2971434622A5056204605 @default.
• W2971434622 hasAuthorship W2971434622A5065073273 @default.
• W2971434622 hasAuthorship W2971434622A5073216396 @default.
• W2971434622 hasAuthorship W2971434622A5074986594 @default.
• W2971434622 hasAuthorship W2971434622A5078632164 @default.
• W2971434622 hasAuthorship W2971434622A5088870232 @default.
• W2971434622 hasBestOaLocation W29714346221 @default.
• W2971434622 hasConcept C121608353 @default.
• W2971434622 hasConcept C126322002 @default.
• W2971434622 hasConcept C143998085 @default.
• W2971434622 hasConcept C2776212926 @default.
• W2971434622 hasConcept C2776694085 @default.
• W2971434622 hasConcept C2778019345 @default.
• W2971434622 hasConcept C2778239845 @default.
• W2971434622 hasConcept C2778695046 @default.
• W2971434622 hasConcept C2781187634 @default.
• W2971434622 hasConcept C2781230642 @default.
• W2971434622 hasConcept C2781451048 @default.
• W2971434622 hasConcept C502942594 @default.
• W2971434622 hasConcept C526805850 @default.
• W2971434622 hasConcept C71924100 @default.
• W2971434622 hasConceptScore W2971434622C121608353 @default.
• W2971434622 hasConceptScore W2971434622C126322002 @default.
• W2971434622 hasConceptScore W2971434622C143998085 @default.
• W2971434622 hasConceptScore W2971434622C2776212926 @default.
• W2971434622 hasConceptScore W2971434622C2776694085 @default.
• W2971434622 hasConceptScore W2971434622C2778019345 @default.
• W2971434622 hasConceptScore W2971434622C2778239845 @default.
• W2971434622 hasConceptScore W2971434622C2778695046 @default.
• W2971434622 hasConceptScore W2971434622C2781187634 @default.
• W2971434622 hasConceptScore W2971434622C2781230642 @default.
• W2971434622 hasConceptScore W2971434622C2781451048 @default.
• W2971434622 hasConceptScore W2971434622C502942594 @default.
• W2971434622 hasConceptScore W2971434622C526805850 @default.
• W2971434622 hasConceptScore W2971434622C71924100 @default.

• next